Substance Use Disorder (SUD)NCT06629740
A Study of a Mobile Phone Application Measuring the Eyes Before and After Medication
A study testing Measurements with a eHealth system in people with Substance Use Disorder (SUD), run by Kontigo Care AB at 1 site in Netherlands.
Trial summary
This is a post-market clinical follow-up study on an approved CE-marked eHealth system where a mobile phone application is used to measure the pupils and eye measurements to monitor the use of different drug substances. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Substance Use Disorder (SUD)
- What is being tested?
- Measurements with a eHealth system
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 34 participants
- Where
- 1 siteNetherlands
- Study dates
- 1 Nov 2024to 18 Mar 2025
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Male or female healthy volunteers.
- Age 18 to 55 years.
- BMI between 18.5-30 kg/m2.
- Weight between 50-100 kg.
- Healthy as determined by the investigator or designee based on pre-investigational medical and surgical history, and health examination at enrollment.
- Women of childbearing potential (defined as all women who are not surgically sterile or postmenopausal for at least 1 year prior to enrollment) must have a negative urine pregnancy test at enrollment and at visit 2 and must agree to use a medically acceptable contraception from enrollment until clinical investigation completion.
Show all 9Show fewer
- No current drug usage defined as a negative urine drug test at enrollment and at visit 2.
- Able to use Previct Drugs after initial training (defined as successfully performing a test set after trying maximum three times per measurement).
- Voluntarily agrees to participate and has duly singed the Informed Consent Form.
Who cannot join
- Participating in another clinical investigation which may affect the clinical investigation outcome according to clinical judgement.
- Previously participated in the KCClin01 investigation.
- Pregnant or lactating.
- Blind and/or deaf.
- Clinically abnormal ECG, according to the investigator. QTcF time above 450 ms at enrollment.
- Resting heart rate above 90 BPM.
Show all 20Show fewer
- Current or recent history of alcohol misuse assessed by AUDIT where ≥6 points for women or ≥8 points for men indicates a potential misuse.
- Current or history of psychiatric disorder or drug misuse assessed by M.I.N.I where the outcome will be based on clinical judgement.
- Any disease or condition that may influence pupillary reflexes based on clinical judgement.
- Undergone eye surgery that may influence pupillary reflexes based on clinical judgement.
- Ongoing treatment with medications which may interfere with eye measurements based on clinical judgement.
- Ongoing treatment with medications which may interfere with any of the medicinal products to be used.
- History or presence of allergy or serious reaction to the medicinal products to be used.
- History or presence of cardiovascular disease, e.g., arteriosclerosis, hypertension, or cor pulmonale.
- History or presence of sleep-related breath disorder.
- History or presence of gastrointestinal disease, e.g., paralytic ileus, acute abdomen, delayed gastric emptying, or chronic constipation.
- History or presence of pulmonary disease, e.g., acute pulmonary insufficiency, severe respiratory depression with hypoxia, chronic obstructive lung disease, or bronchial asthma.
- History or presence of autoimmune neuromuscular disease, e.g., myasthenia gravis.
- Not able to read or understand the local language.
- Any other condition that as judged by the investigator may make the follow-up or investigation inappropriate.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Post-market Clinical Follow-up Investigation in Healthy Volunteers Measuring Eye Parameters to Verify Performance and Safety of Previct® Drugs for Monitoring of Patients in Treatment of Substance Use Disorder
This is a post-market clinical follow-up study on an approved CE-marked eHealth system where a mobile phone application is used to measure the pupils and eye measurements to monitor the use of different drug substances. The goal of the study is to collect additional information when using the system and to improve the current models for indicating the use of cannabinoids and phenethylamines.
Drug intake of cannabinoid or phenethylamine will in this study be simulated using two commonly used medicines.
The study will include healthy volunteers where each participant will participate in the study for approximately 10 days. The participant will be using the mobile phone application for about a week, first at the clinic and then in the home environment. After approximately a week the participant will visit the clinic to be administered with the selected medicine whereafter the mobile phone application will be used for up to 5 hours. A final phone call will be taken place at approximately day 10, whereafter the participant has completed the study.
Read the detailed description
This is a controlled, prospective, post-market clinical follow-up study that aims to collect additional data on performance and safety of the CE-marked eHeatlh system Previct Drugs. Previct Drugs is intended to be used in treatment of substance use disorder (SUD) to support and monitor patients' treatment. The system relies on self-administered eye scanning performed with a mobile phone application where the analysis of the eye´s reaction on intake of drug substances gives an indication of different drug substances. The clinical data collected in this study is an important step to verify and improve the algorithms of Previct Drugs, and to improve the mathematical models for indicating the use of the substances cannabinoids and phenethylamines.
Drug intake will in this study be simulated by a controlled single application of commonly used medicines from cannabinoids and phenethylamine.
The study will enroll and follow 30 male and female healthy volunteers for participation of approximately 10 days. The study will consist of two visits to the clinic, and one follow-up telephone call before the participant has completed the study. Baseline data will be collected at the first visit on Day 0, including usage of Previct Drugs, followed by usage of Previct Drugs in the home environment for about one week. At visit 2 on Day 7, the subject will be administered with the medicine he/she has been randomized to and thereafter use Previct Drugs for up to 5 hours. A final follow-up telephone call will take place approximately at day 10 before the participant has completed the study.
- Conditions
- Substance Use Disorder (SUD)
- Being tested
- Measurements with a eHealth system
- Keywords
- substance use disorder, post-market clinical follow-up, eye monitoring, smartphone, app
- Medical subject headings
- Substance-Related Disorders, Alzheimer Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Measurements with a eHealth systemDevice
The eHealth system Previct Drugs is a CE marked medical device intended to be used in treatment of substance use disorder (SUD) to support and monitor patients' treatment. Previct Drugs consists of a mobile phone application used to perform self-administered eye-scanning, a web-based careportal used by the caregiver, a database for storage, handling, and analysis of reported data, and an admin portal for the manufacturer to register and administer customers. In this study, Previct Drugs will be used by healthy volunteers for performing measurements before and after intake of a commonly used medicine to simulate drug intake.
| Study group | Role | What they receive |
|---|---|---|
| Cannabinoid | Experimental | A single administration of cannabinoid where a CE-marked eHealth system will be used before and after intake. Receives: Device: Measurements with a eHealth system |
| Phenethylamine | Experimental | A single administration of phenethylamine where a CE-marked eHealth system will be used before and after intake. Receives: Device: Measurements with a eHealth system |
What is being measured
The primary outcome is the main question the study is designed to answer.
Verify if Self-administered Eye Scanning Using a Mobile Phone Application, Using Native Key Features (Alone or in Predefined Combination(s)), Can Indicate Use of Each Medicine (D1-D2).
For each medicinal product (D1-D2), number of changed key features from baseline to the LC-MS/MS (Liquid Chromatography Tandem Mass-Spectroscopy) verified peak concentration in plasma after administration of medicinal product at visit 2 using native pupillograms. Each of the 21 key features represents an eye characteristic (such as pupil size, iris position, and the similar). A key feature is considered "changed" if the difference between averages at baseline and peak concentration is significant (p<0.05). Key features were available from two conditions, one condition where pupillograms and corresponding key features were collected in dim ambient light (50 Lux) and one condition where pupillograms and corresponding key features were collected in bright ambient light (500 Lux). The Outcome Measure is reported for both ambient light conditions.
Measured: Day 7 (+/- 2 days)
Secondary outcomes (5)
Verify if Self-administered Eye Scanning Using a Mobile Phone Application, After Refinement of the Method for Establishing Key Features (Alone or in Predefined Combination(s)), Can Indicate the Use of Each Medicine (D1-D2).
For each medicinal product (D1-D2), number of changed key features from baseline to the LC-MS/MS (Liquid Chromatography Tandem Mass-Spectroscopy) verified peak concentration in plasma after administration of medicinal product at visit 2 using refined pupillograms. Each of the 21 key features represents an eye characteristic (such as pupil size, iris position, and the similar). A key feature is considered "changed" if the difference between averages at baseline and peak concentration is significant (p<0.05). Key features were available from two conditions, one condition where pupillograms and corresponding key features were collected in dim ambient light (50 Lux) and one condition where pupillograms and corresponding key features were collected in bright ambient light (500 Lux). The Outcome Measure is reported for both ambient light conditions.
Measured: Day 7 (+/- 2 days)
Evaluate the First and Last Measurement Occasion After Medicine Intake of D1 or D2 When Refined Key Eye Features, Alone or in Predefined Combination(s), Differ From Baseline.
For each medicinal product, refined pupillogram key features were evaluated for significant change from baseline at predefined post-dose measurement occasions. The reported value is the first or last scheduled measurement occasion start time at which a statistically significant change from baseline was observed for the study population. Values therefore represent study-level time-point identifiers from a significance analysis and are not participant-level measurements; measures of central tendency and dispersion are not applicable. Up to 5 key features with the lowest p-values were reported separately for each ambient light condition (50 lux and 500 lux). Consequently, 8 key features were reported for cannabinoid (3 at 50 lux and 5 at 500 lux) and 10 for phenethylamine (5 at 50 lux and 5 at 500 lux). Measurement occasions were 10*, 30, 60, 120, 180, 240, 360 and 420¤ min post-dose (*cannabinoid only; ¤phenethylamine only).
Measured: Day 7 (+/- 2 days)
Evaluate the Difference Between Refined Drug naïve Test Data Collected at the Clinic and Compared With Tests Performed in Home Environment.
For each subject, differences between refined key feature values taken at baseline (at study site) and measurements taken in home environment under similar light conditions. This outcome relates to data collected prior to administration of medicinal product, meaning the two arms contain data from identical conditions and can be merged into one group. Reporting is performed only for Dbase, Dcon, MCA, MCV. Two different ambient light conditions, as measured with the smartphones, is compared for dimmed (20-150 Lux) and bright (150-500 Lux) light. When the difference between data from baseline (at the clinic) and data from home condition is non-significant (using p<0.05 as significance level), then the key feature is reported similar for the designated ambient light condition.
Measured: From Day 0 to Day 7 (+ 2 days)
Evaluate if the Refined Drug naïve Key Features (Alone or in Predefined Combination(s)), Collected at Baseline Differs From Data Collected at Peak Plasma Concentration Under the Influence of D1-D2 Without Compensating for Intra-individual Variation.
For each medicinal product, refined pupillogram key features were evaluated for change between baseline and the LC-MS/MS-verified peak plasma concentration following administration at Visit 2. A key feature represents an ocular characteristic derived from the pupillogram (e.g., pupil size or iris position). Unlike the primary, secondary 1 and secondary 2 analysis, baseline values were not normalized for intra-individual variation. For each selected key feature, measurements obtained at peak concentration were compared with baseline measurements across participants. A key feature was counted as changed if the baseline-versus-peak comparison was statistically significant (p<0.05). Results are reported as the number of changed key features among the five selected key features for reporting in Secondary Outcome 1 (up to five key features with the lowest p-values for each ambient light condition). Key features were evaluated under dim (50 lux) and bright (500 lux) ambient light conditions.
Measured: Day 7 (+/- 2 days)
Incidence and Severity of Adverse Events.
The incidence and severity of adverse events associated with Previct Drugs.
Measured: From enrollment until end of follow-up, up to telephone follow-up call latest at Day 14.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Oct 2024
- Study start1 Nov 2024
- Primary completion17 Mar 2025
- Study completion18 Mar 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Substance Use Disorder (SUD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Subjects will be randomized into one of two arms for deciding upon which of the two medicines (phenethylamine or cannabinoid) to be administered through a single application at visit 2. The randomization will also take into account which one of three different smartphone brands with the Previct Drugs mobile phone application preinstalled to be used by the subject during the study. The study aims to enroll 30 subjects, 12 subjects in the phenethylamine group and 18 subjects in the cannabinoid group. The dropout rate is estimated to 10%.
- Masking
- None (open label)
- Enrolment
- 34 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kontigo Care AB
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Markku Hämäläinen, PhD, Study chair, Kontigo Care AB
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06629740
- Sponsor's protocol ID
- KCClin03
- Other IDs
- NL87202.058.24
- Status last verified
- Jun 2026
- First submitted
- 1 Oct 2024
- Last updated
- 20 Jul 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
For adverse events recording and reporting, the terminology and procedure defined in ISO 14155:2020 and the EU MDR 2017/745 is followed.
Study at a glance
From the registry record, last updated by the sponsor on 20 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Post-market Clinical Follow-up Investigation in Healthy Volunteers Measuring Eye Parameters to Verify Performance and Safety of Previct® Drugs for Monitoring of Patients in Treatment of Substance Use Disorder
- ClinicalTrials.gov ID
- NCT06629740
- Acronym / sponsor ID
- KCClin03
- Conditions
- Substance Use Disorder (SUD)
- Keywords
- substance use disorder, post-market clinical follow-up, eye monitoring, smartphone, app
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 34 participants (actual)
- Lead sponsor
- Kontigo Care ABIndustry (pharma, biotech, devices)
- Study start
- 1 Nov 2024 (actual)
- Primary completion
- 17 Mar 2025 (actual)
- Study completion
- 18 Mar 2025 (actual)
- First posted
- 8 Oct 2024 (actual)
- Results
- Posted 20 Jul 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a post-market clinical follow-up study on an approved CE-marked eHealth system where a mobile phone application is used to measure the pupils and eye measurements to monitor the use of different drug substances. The goal of the study is to collect additional information when using the system and to improve the current models for indicating the use of cannabinoids and phenethylamines.
Drug intake of cannabinoid or phenethylamine will in this study be simulated using two commonly used medicines.
The study will include healthy volunteers where each participant will participate in the study for approximately 10 days. The participant will be using the mobile phone application for about a week, first at the clinic and then in the home environment. After approximately a week the participant will visit the clinic to be administered with the selected medicine whereafter the mobile phone application will be used for up to 5 hours. A final phone call will be taken place at approximately day 10, whereafter the participant has completed the study.
Detailed description
This is a controlled, prospective, post-market clinical follow-up study that aims to collect additional data on performance and safety of the CE-marked eHeatlh system Previct Drugs. Previct Drugs is intended to be used in treatment of substance use disorder (SUD) to support and monitor patients' treatment. The system relies on self-administered eye scanning performed with a mobile phone application where the analysis of the eye´s reaction on intake of drug substances gives an indication of different drug substances. The clinical data collected in this study is an important step to verify and improve the algorithms of Previct Drugs, and to improve the mathematical models for indicating the use of the substances cannabinoids and phenethylamines.
Drug intake will in this study be simulated by a controlled single application of commonly used medicines from cannabinoids and phenethylamine.
The study will enroll and follow 30 male and female healthy volunteers for participation of approximately 10 days. The study will consist of two visits to the clinic, and one follow-up telephone call before the participant has completed the study. Baseline data will be collected at the first visit on Day 0, including usage of Previct Drugs, followed by usage of Previct Drugs in the home environment for about one week. At visit 2 on Day 7, the subject will be administered with the medicine he/she has been randomized to and thereafter use Previct Drugs for up to 5 hours. A final follow-up telephone call will take place approximately at day 10 before the participant has completed the study.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Subjects will be randomized into one of two arms for deciding upon which of the two medicines (phenethylamine or cannabinoid) to be administered through a single application at visit 2. The randomization will also take into account which one of three different smartphone brands with the Previct Drugs mobile phone application preinstalled to be used by the subject during the study. The study aims to enroll 30 subjects, 12 subjects in the phenethylamine group and 18 subjects in the cannabinoid group. The dropout rate is estimated to 10%.
| Arm | Type | Receives |
|---|---|---|
| Cannabinoid | Experimental | Device: Measurements with a eHealth systemA single administration of cannabinoid where a CE-marked eHealth system will be used before and after intake. |
| Phenethylamine | Experimental | Device: Measurements with a eHealth systemA single administration of phenethylamine where a CE-marked eHealth system will be used before and after intake. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (9 listed)
- Male or female healthy volunteers.
- Age 18 to 55 years.
- BMI between 18.5-30 kg/m2.
- Weight between 50-100 kg.
- Healthy as determined by the investigator or designee based on pre-investigational medical and surgical history, and health examination at enrollment.
Key exclusion criteria (20 listed)
- Participating in another clinical investigation which may affect the clinical investigation outcome according to clinical judgement.
- Previously participated in the KCClin01 investigation.
- Pregnant or lactating.
- Blind and/or deaf.
- Clinically abnormal ECG, according to the investigator. QTcF time above 450 ms at enrollment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Measurements with a eHealth systemThe eHealth system Previct Drugs is a CE marked medical device intended to be used in treatment of substance use disorder (SUD) to support and monitor patients' treatment. Previct Drugs consists of a mobile phone application used to perform self-administered eye-scanning, a web-based careportal used by the caregiver, a database for storage, handling, and analysis of reported data, and an admin portal for the manufacturer to register and administer customers. In this study, Previct Drugs will be used by healthy volunteers for performing measurements before and after intake of a commonly used medicine to simulate drug intake. | Device | Cannabinoid, Phenethylamine |
Primary outcome
Verify if Self-administered Eye Scanning Using a Mobile Phone Application, Using Native Key Features (Alone or in Predefined Combination(s)), Can Indicate Use of Each Medicine (D1-D2).
Time frame: Day 7 (+/- 2 days)
For each medicinal product (D1-D2), number of changed key features from baseline to the LC-MS/MS (Liquid Chromatography Tandem Mass-Spectroscopy) verified peak concentration in plasma after administration of medicinal product at visit 2 using native pupillograms. Each of the 21 key features represents an eye characteristic (such as pupil size, iris position, and the similar). A key feature is considered "changed" if the difference between averages at baseline and peak concentration is significant (p<0.05). Key features were available from two conditions, one condition where pupillograms and corresponding key features were collected in dim ambient light (50 Lux) and one condition where pupillograms and corresponding key features were collected in bright ambient light (500 Lux). The Outcome Measure is reported for both ambient light conditions.
5 secondary outcomes
Verify if Self-administered Eye Scanning Using a Mobile Phone Application, After Refinement of the Method for Establishing Key Features (Alone or in Predefined Combination(s)), Can Indicate the Use of Each Medicine (D1-D2).
Time frame: Day 7 (+/- 2 days)
Evaluate the First and Last Measurement Occasion After Medicine Intake of D1 or D2 When Refined Key Eye Features, Alone or in Predefined Combination(s), Differ From Baseline.
Time frame: Day 7 (+/- 2 days)
Evaluate the Difference Between Refined Drug naïve Test Data Collected at the Clinic and Compared With Tests Performed in Home Environment.
Time frame: From Day 0 to Day 7 (+ 2 days)
Evaluate if the Refined Drug naïve Key Features (Alone or in Predefined Combination(s)), Collected at Baseline Differs From Data Collected at Peak Plasma Concentration Under the Influence of D1-D2 Without Compensating for Intra-individual Variation.
Time frame: Day 7 (+/- 2 days)
Incidence and Severity of Adverse Events.
Time frame: From enrollment until end of follow-up, up to telephone follow-up call latest at Day 14.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jul 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- BackgroundFor adverse events recording and reporting, the terminology and procedure defined in ISO 14155:2020 and the EU MDR 2017/745 is followed.
- Individual participant dataSharing planned: Undecided
Related trials for Substance Use Disorder (SUD)
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Active, not recruiting
EXHIT ENTRE Implementation Trial of High Intensity Versus Low Intensity Strategy
Substance Use Disorders, Opioid Use Disorder, Severe
Recruiting
The Trans-Led Care Study
Substance Abuse, Substance Addiction
Not yet recruitingObservational study
Disease Intervention Specialist (DIS) for SUD
Substance Use Disorder (SUD), Opioid Use Disorder
RecruitingEarly Phase 1
Evaluating Pain Control Strategies in Postpartum Patients on Opioid Use Disorder Medications.
Substance Use Disorder (SUD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Markku Hämäläinen, PhD study chair
Kontigo Care AB
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Measurements with a eHealth system in people with Substance Use Disorder (SUD), run by Kontigo Care AB at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 20 Jul 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Verify if Self-administered Eye Scanning Using a Mobile Phone Application, Using Native Key Features (Alone or in Predefined Combination(s)), Can Indicate Use of Each Medicine (D1-D2). (time frame: Day 7 (+/- 2 days)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06629740, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jul 2026.